Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Masked, Multicenter Study to Assess the Safety and Efficacy of CLS-TA, Triamcinolone Acetonide Injectable Suspension in the Treatment of Subjects With Macular Edema Following Uveitis

Trial Profile

A Randomized, Masked, Multicenter Study to Assess the Safety and Efficacy of CLS-TA, Triamcinolone Acetonide Injectable Suspension in the Treatment of Subjects With Macular Edema Following Uveitis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 09 Feb 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Triamcinolone (Primary)
  • Indications Retinal oedema; Uveitis
  • Focus Therapeutic Use
  • Acronyms DOGWOOD
  • Sponsors Clearside Biomedical
  • Most Recent Events

    • 01 May 2019 According to a Clearside Biomedical media release, pooled results from this and other two trials (PEACHTR and AZALEA) were presented at the merican Uveitis Society Spring Meeting 2019.
    • 19 Feb 2019 According to a Clearside Biomedical media release, a combined analysis on the results from the AZALEA, DOGWOOD, and PEACHTREE studies was presented at the 42nd Annual Macula Society Meeting held February 13-16, 2019 in Bonita Springs, Florida.
    • 09 Nov 2016 According to a Clearside Biomedical media release, data from the study has been presented at the American Society of Retina Specialists annual meeting in August 2016.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top